IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Via La Masa 19, 20156 Milano, Italy.
1] Clinica Neurologica, Università di Perugia, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, 06156 Perugia, Italy [2] IRCCS-Fondazione S. Lucia, 00179 Roma, Italy.
Cell Death Dis. 2014 Jan 23;5(1):e1019. doi: 10.1038/cddis.2013.559.
Altered synaptic function is considered one of the first features of Alzheimer disease (AD). Currently, no treatment is available to prevent the dysfunction of excitatory synapses in AD. Identification of the key modulators of synaptopathy is of particular significance in the treatment of AD. We here characterized the pathways leading to synaptopathy in TgCRND8 mice and showed that c-Jun N-terminal kinase (JNK) is activated at the spine prior to the onset of cognitive impairment. The specific inhibition of JNK, with its specific inhibiting peptide D-JNKI1, prevented synaptic dysfunction in TgCRND8 mice. D-JNKI1 avoided both the loss of postsynaptic proteins and glutamate receptors from the postsynaptic density and the reduction in size of excitatory synapses, reverting their dysfunction. This set of data reveals that JNK is a key signaling pathway in AD synaptic injury and that its specific inhibition offers an innovative therapeutic strategy to prevent spine degeneration in AD.
突触功能改变被认为是阿尔茨海默病(AD)的最早特征之一。目前,尚无治疗方法可预防 AD 中兴奋性突触的功能障碍。鉴定突触病的关键调节剂在 AD 的治疗中具有特别重要的意义。我们在这里描述了 TgCRND8 小鼠中导致突触病的途径,并表明 c-Jun N-末端激酶(JNK)在认知障碍出现之前在脊柱上被激活。JNK 的特异性抑制,其特异性抑制肽 D-JNKI1,可防止 TgCRND8 小鼠的突触功能障碍。D-JNKI1 避免了突触后密度中突触后蛋白和谷氨酸受体的丢失以及兴奋性突触的缩小,从而恢复了其功能障碍。这组数据表明 JNK 是 AD 突触损伤的关键信号通路,其特异性抑制为预防 AD 中的脊柱退化提供了一种创新的治疗策略。